McKesson consensus picture on Wall Street, shares tracked against healthcare peers
25.06.2026 - 16:26:45 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-25, 16:26.
McKesson (US58155Q1031) remains a closely watched name on the NYSE as analysts refine their earnings and valuation assumptions for the U.S. drug distributor. The focus on Thursday is the consolidated Wall Street consensus for revenue growth, margins and earnings per share over the coming fiscal years, according to current analyst data.
What analysts currently expect
On MarketScreener, 15 to 20 covering analysts are listed for McKesson with a majority rating the stock as Buy or Outperform, while a smaller group stays Neutral or Hold, illustrating a broadly positive but not euphoric stance on the shares as of late June 2026 MarketScreener consensus overview. The average twelve?month price target in this sample sits noticeably above the recent trading range, implying further upside in the analysts’ base case.
Several large houses, including JPMorgan, Goldman Sachs and UBS, are among the institutions that follow major U.S. healthcare distributors such as McKesson, Cardinal Health and Cencora, using relative valuation and margin trends as key inputs to their recommendations Reuters sector commentary on U.S. drug distributors. According to recent estimates compiled on financial data platforms, consensus expects McKesson to deliver mid?single?digit annual revenue growth with earnings per share increasing at a faster pace due to margin management and buybacks.
How McKesson compares in its sector
In the U.S. wholesale healthcare space, McKesson competes primarily with Cardinal Health and Cencora, formerly AmerisourceBergen, all of which trade on the NYSE and sit in the same broad healthcare distribution segment Bloomberg analysis of healthcare distributors. Market data from these peers show a focus on low operating margins but very high revenue volumes, with investors comparing free cash flow conversion and capital returns across the group.
McKesson’s market capitalization places it among the larger healthcare distributors globally, alongside U.S. peers and international operators such as Germany’s Phoenix group, even though Phoenix is not listed, which underscores the scale of the listed U.S. players. Sector reviews by investment banks regularly contrast McKesson’s return on invested capital and working?capital efficiency with that of Cardinal Health and Cencora, forming an important part of analyst stock calls.
All news and analysis on the McKesson shares
Further regulatory filings, earnings releases and sector commentary provide additional context for the McKesson investment case.
How McKesson earns its money
McKesson generates most of its revenue by distributing pharmaceuticals and medical products to pharmacies, hospitals and other healthcare providers across North America and selected international markets, according to the company’s latest annual report and corporate information. The group also operates technology and specialty care solutions for oncology and other therapeutic areas, and offers supply?chain and automation services to support healthcare customers.
Where the stock trades today
The McKesson shares (US58155Q1031) trade on the NYSE in U.S. dollars; recent indicative quotes on June 25, 2026 show levels in the high?700?dollar range for the U.S. listing.
Key data on the McKesson shares
- Company: McKesson Corporation
- ISIN: US58155Q1031
- WKN: 893953
- Ticker: MCK
- Trading venue: NYSE
- Price (as of 2026-06-25, 14:00): 773.15 USD
- Market cap: around 100 billion USD (as of late June 2026)
- Sector / industry: Healthcare distribution and services
- Index membership: S&P 500
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any securities. All data are based on publicly available sources believed to be reliable but cannot be guaranteed.
